MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dyskinesias"

  • 2017 International Congress

    Unusual MRI findings of the syndrome of acute bilateral basal ganglia lesions in diabetic uremia with hyperglycemia associated dyskinesia

    P.-Y. Chen, A. Gutfreund, K. Brockmann, I. Wurster, G. Eschweiler, F. Metzger, W. Maetzler, D. Berg (Taipei, Taiwan)

    Objective: To describe the unusual image findings and clinical manifestations of the syndrome of acute bilateral basal ganglia lesions in a diabetic uremic patient with…
  • 2017 International Congress

    Levodopa effect and motor function in late stage Parkinson’s disease

    K. Rosqvist, P. Odin, M. Horne, P. Hagell, S. Iwarsson, M. Nilsson (Lund, Sweden)

    Objective: To assess responsiveness to Levodopa (L-dopa) in patients with late stage Parkinson’s disease (PD). Moreover, to investigate if the L-dopa effect is stable or…
  • 2017 International Congress

    Altered somtatosensory cortex neuronal activity in a rat model of Parkinson`s disease and levodopa-induced dyskinesias

    K. Schwabe, X. Jin, J. Krauss, M. Alam (Hannover, Germany)

    Objective: In this study, we explored the neuronal firing activity of excitatory pyramidal cells and inhibitory interneurons in the forelimb region of the primary somatosensory…
  • 2017 International Congress

    Using cognitive computing to identify compounds with antidyskinetic potential for Parkinson’s disease

    N. Visanji, A. Lacoste, S. Ezell, S. Spangler, E. Argentinis, J. Brotchie, A. Lang, T. Johnston (Toronto, ON, Canada)

    Objective: IBM Watson for Drug Discovery (WDD) is a platform that analyzes vast quantities of scientific data to help researchers identify hidden connections and formulate…
  • 2017 International Congress

    Levodopa/carbidopa Intestinal Gel Can Improve Both Motor and Non-Motor Experiences of Daily Living in Parkinson’s Disease: An Open-Label Study

    N. Kovacs, A. Juhász, Z. Aschermann, P. Ács, J. Janszky, M. Kovács, A. Makkos, M. Harmat, D. Tényi, K. Katádi, S. Komoly, A. Takáts, A. Tóth, H. Nagy, P. Klivényi, G. Dibó, L. Dézsi, D. Zádori, Á. Annus, L. Vécsei, L. Varannai (Pécs, Hungary)

    Objective: : Our aim was to determine if the MDS-UPDRS and UDysRS could detect improvement in the experiences of daily living following 1-year LCIG treatment.…
  • 2017 International Congress

    Dynamic stability during turning in people with Parkinson’s disease

    C. Curtze, P. Fino, S. Smith, P. Carlson-Kuhta, J. Nutt, F. Horak (Portland, OR, USA)

    Objective: The goal of this study is to determine the contributions of dyskinesia to abnormal turning mechanisms.   Background: The ability to turn safely while…
  • 2017 International Congress

    Mechanisms of sub-anesthetic ketamine infusions to reduce L-DOPA-induced dyskinesia: effects on striatal mTOR signaling and beta band oscillations in striatum and motor cortex

    M. Bartlett, A. Flores, T. Ye, H. Dollish, K. Doyle, S. Cowen, S. Sherman, T. Falk (Tucson, AZ, USA)

    Objective: To evaluate mechanism of long-term activity of sub-anesthetic ketamine infusion to reduce L-DOPA-induced dyskinesia (LID). Background: We have published preclinical evidence and patient case…
  • 2017 International Congress

    Serotonin–to–dopamine transporter ratios in Parkinson’s dyskinesias: the longitudinal study

    A.-A. Roussakis, N. Lao-Kaim, A. Martin-Bastida, N. Valle-Guzman, M. Politis, T. Foltynie, R. Barker, P. Piccini (London, United Kingdom)

    Objective: This study was designed to detect whether in Parkinson’s disease (PD) the putaminal serotonin–over–dopamine transporter ratio has a threshold that is critical for the…
  • 2017 International Congress

    Reliability of Continuous Parkinson’s Assessment Using Wearables

    D. Heldman, E. Urrea Mendoza, N. Mennucci, C. Zimmerman, J. Giuffrida, A. Hadley, Z. Mari, M. Burack, I. Itin, F. Revilla (Cleveland, OH, USA)

    Objective: To evaluate test-retest reliability and determine the optimal number of days of use for wearable sensors and a mobile software app to continuously and…
  • 2017 International Congress

    The clinically-available anti-depressant mirtazapine alleviates both psychosis and dyskinesia in the MPTP-lesioned marmoset

    I. Frouni, S. Nuara, N. Veyres, C. Kwan, M.-J. Harraka, V. Nafade, L. Sid-Otmane, J. Gourdon, H. Adjia, P. Huot (Montreal, QC, Canada)

    Objective: To determine the effect of mirtazapine, a clinically-available anti-depressant, on psychosis and dyskinesia in Parkinson’s disease (PD). Background: Psychosis and dyskinesia cause significant morbidity…
  • « Previous Page
  • 1
  • …
  • 38
  • 39
  • 40
  • 41
  • 42
  • …
  • 49
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley